Bibliography
- LEE JW, DEVANARAYAN V, BARRETT YC et al.: Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. (2006) 23(2):312-328.
- MAZUMDER A, WANG Y: Gene-expression signatures in oncology diagnostics. Pharmacogenomics (2006) 7(8):1167-1173.
- CARNEY WP: Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev. Mol. Diagn. (2007) 7(3):309-319.
- RINGGER NC, O'STEEN BE, BRABHAM JG et al.: A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J. Neurotrauma (2004) 21(10):1443-1456.
- LIM YP, BENDELJA K, OPAL SM, SIRYAPORN E, HIXSON DC, PALARDY JE: Correlation between mortality and the levels of inter-α inhibitors in the plasma of patients with severe sepsis. J. Infect. Dis. (2003) 188(6):919-926.
- WU R, CUI X, LIM YP et al.: Delayed administration of human inter-α inhibitor proteins reduces mortality in sepsis. Crit. Care Med. (2004) 32(8):1747-1752.
- BURCZYNSKI ME, OESTREICHER JL, CAHILLY MJ et al.: Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr. Mol. Med. (2005) 5(1):83-102.
- VISWANATHAN CT, BANSAL S, BOOTH B et al.: Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. (2007).
- ISLER JA, VESTERQVIST OE, BURCZYNSKI ME: Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics (2007) 8(4):353-368.